{"id":4875,"date":"2016-06-03T11:00:00","date_gmt":"2016-06-03T11:00:00","guid":{"rendered":"https:\/\/aspree.org\/aus\/?p=4875"},"modified":"2021-08-02T23:23:09","modified_gmt":"2021-08-02T23:23:09","slug":"aspree-and-us-aspirin-guidelines","status":"publish","type":"post","link":"https:\/\/aspree.org\/aus\/aspree-and-us-aspirin-guidelines\/","title":{"rendered":"ASPREE and US aspirin guidelines"},"content":{"rendered":"\r\n<h2 class=\"wp-block-heading\">Researchers cite\u00a0ASPREE to inform aspirin guidelines in older adults<\/h2>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p>International researchers anticipate findings from the\u00a0ASPREE study will help fill a knowledge gap\u00a0that led to\u00a0the exclusion of older people from recent U.S. aspirin guidelines.\u00a0Several\u00a0articles in the Annals of Internal Medicine, which cited or discussed the ASPREE study, were published alongside the release of the U.S. Preventive Services Task Force (USPSTF) final recommendations on aspirin and disease prevention.<\/p>\r\n\r\n\r\n\r\n<p><strong>Lack of Evidence:<\/strong><\/p>\r\n\r\n\r\n\r\n<p>The\u00a0<a href=\"http:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/aspirin-to-prevent-cardiovascular-disease-and-cancer\" target=\"_blank\" rel=\"noreferrer noopener\">USPSTF<\/a>\u00a0found a shortage of\u00a0high quality scientific studies meant they could not fully determine the balance of benefits and risks of aspirin for the prevention of cardiovascular disease (CVD) such as heart attack and stroke, and colorectal cancer (CRC) in people aged 70 years and older.<br \/>\u201cThere is not enough available evidence on the benefits and harms of aspirin use in adults younger than age 50 and those 70 or older to recommend for or against its use in preventing CVD and CRC.\u201d\u00a0<a href=\"\/wp-content\/uploads\/sites\/2\/2021\/06\/aspr-cvccrc-finalrsfactApril2016.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">USPSTF consumer guide<\/a>\u00a0said.<\/p>\r\n\r\n\r\n\r\n<p><strong>Peer-reviewed response:<\/strong><\/p>\r\n\r\n\r\n\r\n<p>To coincide with the release of the USPSTF findings, several international researchers published papers which cited the ASPREE study to help\u00a0address the knowledge gap:<\/p>\r\n\r\n\r\n\r\n<ul>\r\n<li>\u201cMore\u00a0robust and comprehensive trial data involving representative patient samples on low-dose aspirin use for primary prevention should address all-cause mortality; CVD and cancer incidence and mortality; bleeding and other major harms; and emerging potential benefits, such as preventing cognitive decline. Multiple ongoing trials (56) (54 \u201357) \u2026..will provide some of this essential information\u201d (<a href=\"http:\/\/annals.org\/article.aspx?articleid=2513175&amp;resultClick=3\" target=\"_blank\" rel=\"noreferrer noopener\">Whitlock EP, et al. Bleeding Risks<\/a>\u00a0<a href=\"http:\/\/annals.org\/article.aspx?articleid=2513175&amp;resultClick=3\">with Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. online 12 April 2016; doi:10.7326\/M15-2112<\/a>)<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<ul>\r\n<li>\u201cOn the basis of relatively limited and generally lower-quality evidence, we conclude that the most consistent evidence of subpopulation differences in aspirin use was an enhanced effect on MI in older age<br \/>groups. A large ongoing trial of 19 000 participants aged 70 years or older may confirm this finding (50) (<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27064410\" target=\"_blank\" rel=\"noreferrer noopener\">Guirguis-Blake JM, et al. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med. online 12 April 2016 doi:10.7326\/M15-211<\/a>)<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<ul>\r\n<li>\u00a0\u201cThe primary data for aspirin\u2019s effects on a range of health outcomes have not changed substantially over the past several years, but the field is poised to provide additional data in the near future. Several large trials are in progress (77) (77\u2013 80).\u201d (<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27064482\" target=\"_blank\" rel=\"noreferrer noopener\">Chubak J, et al. Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services<br \/>Task Force. Ann Intern Med. online 12 April 2016 doi:10.7326\/M15-2117<\/a>)<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<ul>\r\n<li>\u201cResults from the ongoing ASPREE (Aspirin in Reducing Events in the Elderly) trial (56) may help to fill data gaps among older populations.\u201d (<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27064573\" target=\"_blank\" rel=\"noreferrer noopener\">Dehmer SP, et al. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Ann Intern Med. online 12 April 2016 doi:10.7326\/M15-2129<\/a>)<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p>Editorial by Oxford University Professor Colin Baigent in the Annal of Internal Medicine, highlighted the importance of research on health recommendations, \u201c..we should not rush to judgement with inadequate data. Instead, we should encourage completion (and long-term follow-up) of the ongoing trials so that the quality of the evidence in future years provides a firm foundation for public policy.\u201d<\/p>\r\n\r\n\r\n\r\n<p><strong>Who was included in the recommendations?<\/strong><\/p>\r\n\r\n\r\n\r\n<p>The USPSTF found sufficient evidence to find aspirin could help prevent CVD and CRC in people aged 50 to 69 years who are at increased risk of developing CVD.<\/p>\r\n\r\n\r\n\r\n<p>The American Academy of Family Physicians has adopted the USPSTF\u2019s aspirin recommendations.\u00a0Results from the ASPREE study are expected in 2018.<\/p>\r\n\r\n\r\n\r\n<p>Anyone considering taking daily aspirin should always speak to their GP beforehand.<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>The USPSTF found a lack of high quality scientific studies meant they could not fully determine the balance of benefits and risks of aspirin for the prevention of cardiovascular disease (CVD) such as heart attack and stroke, and colorectal cancer (CRC) in people aged 70 years and older.<\/p>\n","protected":false},"author":2,"featured_media":1163,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"1200","footnotes":""},"categories":[17,16],"tags":[28,74],"_links":{"self":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4875"}],"collection":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/comments?post=4875"}],"version-history":[{"count":9,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4875\/revisions"}],"predecessor-version":[{"id":8319,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4875\/revisions\/8319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media\/1163"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media?parent=4875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/categories?post=4875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/tags?post=4875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}